



Simplified Approach for Ovarian-Adnexal Reporting and Data System MRI Risk Stratification System

Alireza Mohamadian^{1, 2}, Behnaz Moradi^{2, 3}

¹Department of Radiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; ²Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences, Tehran, Iran; ³Department of Radiology, Yas Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Keywords: *Ovarian lesion; Magnetic resonance imaging; Apparent diffusion coefficient; O-RADS; Flowchart*

Besides ultrasonography, magnetic resonance imaging (MRI) is a problem-solving modality for the evaluation of ovarian lesions [1]. The Ovarian-Adnexal Reporting and Data System (O-RADS) MRI Risk Stratification System was published in 2022, and these guidelines are now available for radiologists. Despite efforts to prepare user-friendly guidelines, radiologists encounter a complex table of information for matching and diagnosing ovarian lesions [1-3].

Compared to the risk-oriented approach to ovarian lesions presented in recent guideline tables, a lesion-oriented flowchart would be more practical for radiologists [4,5]. Therefore, we summarized the findings of the guidelines in the form of an algorithm to explain how to approach ovarian lesions simply (Fig. 1). To apply this algorithm, it is necessary to be familiar with the guideline details [1] and lexicon [6], along with sufficient experience in diagnosing ovarian lesions.

Received: June 10, 2022 **Revised:** August 18, 2022

Accepted: October 3, 2022

Corresponding author: Behnaz Moradi, MD, Department of Radiology, Yas Hospital Complex, Tehran University of Medical Sciences, North Nejatollahi St, Kharim Khan Ave, Tehran 15987-18311, Iran.

• E-mail: b.moradi80@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

In premenopausal women, the size of the lesion is important, and those with lesions having a maximum diameter of 3 cm should be evaluated for benign lesions. If the ovarian lesion is not typical, is larger than 3 cm, or is found in a postmenopausal woman, fat content should be evaluated.

Only large volume-enhancing lesions that contain fat have an intermediate risk of malignancy and are labeled as O-RADS4. A precise definition of large-volume lesions has not been mentioned in the published O-RADS MRI guidelines [1]. However, in the lexicon, the larger solid portion is described as an “enhancing component of an adnexal lesion that does not fit into the categories of papillary projection, mural nodule, or irregular septation/wall” [6]. Any amount of fat within an ovarian lesion is not enhanced, and any solid component with enhancement within a fat-containing lesion may represent malignancy. Fat-containing lesions below 5 cm that do not exhibit any malignant findings are followed by ultrasound [7].

MRI mainly plays a role in the assessment of lesions with solid components. In patients with a uterus, the risk of malignancy is determined according to the pattern of the curve on dynamic contrast-enhanced (DCE) MRI. In patients who do not have the uterus for any reason, on the other hand, the pattern of solid component enhancement is determinative. While a steady rate of enhancement implies a low risk of malignancy, the shoulder and plateau patterns indicate a moderate to high risk of malignancy that is indistinguishable. If the time-intensity curve is not available on DCE MRI, comparing the enhancement of the solid component of the lesion with the myometrium at 30–40 seconds is helpful.

The role of non-contrast MRI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) maps in the characterization of ovarian lesions is increasing day by day, especially in situations where DCE-MRI is not available in that setting, or the patient has a special clinical condition [8,9]. In the absence of a uterus for any reason, perfusion, kidney failure, or pregnancy, any high signal intensity at $b = 1000$ and low signal intensity in the ADC map can suggest a possibly malignant mass equivalent to O5 (O5EQ). On the other hand, low signal intensity at $b = 1000$ and high signal intensity in the ADC map are considered possibly benign (O3EQ) [8].




Fig. 1. Simplified flowchart for approaching ovarian lesions based on the O-RADS MRI risk stratification system. *Based on the scoring system modified with additional DWI criteria, ¹Adapted from Hottat et al. *Ultrasound in Obstetrics & Gynecology* 2021;57:478-487 [8]. ADC = apparent diffusion coefficient, DCE = dynamic contrast-enhanced, DWI = diffusion-weighted imaging, EQ = equivalent, hem = hemorrhage, 0 = O-RADS score, O-RADS = Ovarian-Adnexal Reporting and Data System, PostMW = postmenopausal women, PreMW = premenopausal women

In general, lesions with a solid component that are labeled O3 or O4 according to the O-RADS MRI Risk Stratification System could be re-evaluated with the application of the additional wall suggested approach [8]. Low signal intensity at b = 1000 and high signal intensity in the ADC map, within the solid component, downgrade the lesion from the O3 and O4 classes to O2EQ and O3EQ, respectively. Furthermore, any high signal intensity at b = 1000 and low signal intensity in the ADC map upgrades the O4 lesion to O5EQ.

Availability of Data and Material

All data generated or analyzed during the study are

included in this published article.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: all authors. Resources: all authors. Software: Alireza Mohamadian. Visualization: Alireza Mohamadian. Supervision: Behnaz Moradi. Writing—original draft: Alireza Mohamadian. Writing—review & editing: Behnaz Moradi.

ORCID iDs

Alireza Mohamadian

<https://orcid.org/0000-0002-3476-8400>

Behnaz Moradi

<https://orcid.org/0000-0003-2698-4872>

Funding Statement

None

REFERENCES

1. Sadowski EA, Thomassin-Naggara I, Rockall A, Maturen KE, Forstner R, Jha P, et al. O-RADS MRI risk stratification system: guide for assessing adnexal lesions from the ACR O-RADS committee. *Radiology* 2022;303:35-47
2. Andreotti RF, Timmerman D, Strachowski LM, Froyman W, Benacerraf BR, Bennett GL, et al. O-RADS US risk stratification and management system: a consensus guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. *Radiology* 2019;294:168-185
3. Reinhold C, Rockall A, Sadowski EA, Siegelman ES, Maturen KE, Vargas HA, et al. Ovarian-adnexal reporting lexicon for MRI: a white paper of the ACR ovarian-adnexal reporting and data systems MRI committee. *J Am Coll Radiol* 2021;18:713-729
4. Mohamadian A, Bayani L, Shakki Katouli F. A simplified approach to ovarian lesions based on O-RADS US risk stratification and management system. *Ultrasonography* 2022 May 30 [Epub]. <https://doi.org/10.14366/usg.22037>
5. Taylor EC, Irshaid L, Mathur M. Multimodality imaging approach to ovarian neoplasms with pathologic correlation. *Radiographics* 2020;41:289-315
6. American College of Radiology. O-RADS MR lexicon categories, terms and definitions. ACR.org Web site. <https://www.acr.org/-/media/ACR/Files/RADS/O-RADS/O-RADS-MR-Lexicon-Terms-Table.pdf>. Accessed July 17, 2022
7. Levine D, Brown DL, Andreotti RF, Benacerraf B, Benson CB, Brewster WR, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. *Radiology* 2010;256:943-954
8. Hottat NA, Van Pachterbeke C, Vanden Houte K, Denolin V, Jani JC, Cannie MM. Magnetic resonance scoring system for assessment of adnexal masses: added value of diffusion-weighted imaging including apparent diffusion coefficient map. *Ultrasound Obstet Gynecol* 2021;57:478-487
9. Sahin H, Panico C, Ursprung S, Simeon V, Chiodini P, Fray A, et al. Non-contrast MRI can accurately characterize adnexal masses: a retrospective study. *Eur Radiol* 2021;31:6962-6973